FDA rejects Intercept’s pitch for NASH as CEO fires back at the agency’s ‘evolving’ guidelines

In a major setback for an already ailing field, the FDA has rejected obeticholic acid, the Intercept Pharmaceuticals compound that would have been the first drug specifically approved to treat NASH.